低剂量化疗联合酪氨酸激酶抑制剂治疗Ph染色体阳性急性淋巴细胞白血病的疗效与安全性
回顾性分析2008年1月1日至2021年7月31日北京大学人民医院217例初诊Ph(+) ALL患者,比较低剂量化疗(78例)与常规剂量化疗(139例)联合TKI诱导治疗的疗效与安全性。两组4周CR率及总CR率无显著差异,低剂量组感染发生率更低、粒细胞缺乏及PLT<20×10(9)/L持续时间更短、红细胞输注量更少。
要点
- 低剂量化疗联合TKI组与常规剂量组4周CR率分别为98.7%和97.0%,差异无统计学意义。
- 低剂量组感染发生率低于常规剂量组(OR=0.444,95%CI 0.227~0.866,P=0.017)。
- 低剂量组粒细胞缺乏持续时间(OR=0.272,95%CI 0.128~0.576,P=0.001)及红细胞输注量(OR=0.309,95%CI 0.147~0.651,P=0.002)低于常规剂量组。
核心结论
- 对于Ph(+) ALL患者,低剂量化疗联合TKI作为一线诱导治疗的疗效与常规剂量化疗相当,且安全性好。
研究设计与样本
- 回顾性分析2008年1月1日至2021年7月31日北京大学人民医院收治的217例初诊Ph(+) ALL患者的临床资料,采用logistics回归和Cox回归分析比较低剂量化疗与常规剂量化疗的疗效及不良反应。
- 低剂量化疗组78例,常规剂量化疗组139例,中位年龄38(10~69)岁。
主要发现
- 低剂量化疗组与常规剂量化疗组4周完全缓解率分别为98.7%和97.0%,差异无统计学意义(P=0.766)。
- 低剂量化疗组与常规剂量化疗组总完全缓解率均为100%,差异无统计学意义(P=1.000)。
- 多因素分析显示化疗剂量对无病生存率、总生存率无显著影响。
- 诱导化疗期间感染发生率低剂量组低于常规剂量组(OR=0.444,95%CI 0.227~0.866,P=0.017)。
- 粒细胞缺乏持续时间低剂量组短于常规剂量组(OR=0.272,95%CI 0.128~0.576,P=0.001),红细胞悬液输注量低剂量组少于常规剂量组(OR=0.309,95%CI 0.147~0.651,P=0.002),PLT<20×10(9)/L持续时间低剂量组短于常规剂量组(OR=0.487,95%CI 0.232~1.022,P=0.057)。
临床怎么用
- 原文结论认为低剂量化疗联合TKI作为Ph(+) ALL一线诱导治疗疗效与常规剂量化疗相当且安全性好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The study aims to explore the efficacy and safety of low-dose chemotherapy combined with tyrosine kinase inhibitor (TKI) as an induction therapy for Philadelphia-chromosomal-positive acute lymphoblastic leukemia (Ph(+) ALL) . Methods: The data of the consecutive newly diagnosed patients with Ph(+) ALL were reviewed. The efficacy and safety of low-dose chemotherapy and conventional-dose chemotherapy combined with TKI were compared. Results: A total of 217 patients with a median age of 38 (10-69) years old were included in this study. 78 patients were in the low-dose chemotherapy group, and 139 patients were in the conventional-dose chemotherapy group. There were no significant differences in the 4-week complete remission (CR) rate (98.7% vs 97.0%, P=0.766) and overall CR rate (100% vs 100%, P=1.000) between the two groups. Multivariate analyses showed that the chemotherapy intensity was not related to the disease-free survival rate and overall survival rate. However, the lower incidence of infection (P=0.017) , the shorter duration of neutropenia (P=0.001) and PLT<20 × 10(9)/L (P=0.057) , and the lower red blood cell transfusion volume (P=0.002) were more common in the low-dose chemotherapy group than in the conventional-dose chemotherapy group. Conclusions: The low-dose chemotherapy is superior to the conventional-dose chemotherapy combined with TKI as induction therapy in Ph(+) ALL with similar efficacy but is safer. 目的: 探讨低剂量化疗联合酪氨酸激酶抑制剂(TKI)作为Ph染色体阳性急性淋巴细胞白血病(Ph(+) ALL)诱导治疗方案的有效性与安全性。 方法: 回顾性分析2008年1月1日至2021年7月31日北京大学人民医院收治的217例初诊Ph(+) ALL患者的临床资料,通过logistics回归和Cox回归分析,比较低剂量化疗与常规剂量化疗的疗效及不良反应。 结果: 研究纳入217例患者,中位年龄38(10~69)岁,低剂量化疗组78例,常规剂量化疗组139例。低剂量化疗组与常规剂量化疗组相比,4周完全缓解(CR)率(98.7%对97.0%,P=0.766)及总CR率(100%对100%,P=1.000)差异均无统计学意义。多因素分析显示,化疗剂量对无病生存率、总生存率无显著影响。而两组诱导化疗期间感染发生率(OR=0.444,95% CI 0.227~0.866,P=0.017)、粒细胞缺乏持续时间(OR=0.272,95% CI 0.128~0.576,P=0.001)、PLT<20×10(9)/L持续时间(OR=0.487,95% CI 0.232~1.022,P=0.057)及红细胞悬液输注量(OR=0.309,95% CI 0.147~0.651,P=0.002)差异有统计学意义,低剂量组均显著低或短于常规剂量化疗组。 结论: 对于Ph(+) ALL患者,低剂量化疗联合TKI作为一线诱导治疗的疗效与常规剂量化疗相当,且安全性好。.
引用
- Wang H, Zhao T, Hu LJ, et al. [The efficacy and safety of low-dose chemotherapy combined with tyrosine kinase inhibitors in the treatment of Philadelphia-chromosomal-positive acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709131. doi:10.3760/cma.j.issn.0253-2727.2022.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。